What are the recommended antibiotics and dosing for a vancomycin‑resistant Enterococcus (VRE) infection?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 13, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Antibiotics for VRE

Linezolid 600 mg IV or PO every 12 hours is the strongest recommendation for most VRE infections, with treatment duration dependent on infection site and clinical response. 1

Treatment by Infection Site

Bacteremia (Bloodstream Infections)

  • First-line: Linezolid 600 mg IV/PO q12h (Strong recommendation, 1C) 1
  • Alternative: High-dose daptomycin 8-12 mg/kg IV daily (Weak recommendation, 2C) 1
    • Consider adding β-lactams (penicillins, cephalosporins, or carbapenems—but NOT cefotaxime or cefazolin) when daptomycin MIC is 3-4 mg/mL 1
    • High-dose (≥9 mg/kg) daptomycin with β-lactams shows better survival than monotherapy, particularly when daptomycin MIC ≤2 mg/L 1
  • Duration: 10-14 days 1

Key mortality data: Meta-analysis showed mortality of 32.8% with linezolid vs 35.7% with daptomycin (RR 1.24, p=0.03), though microbiologic cure rates were comparable at 91% vs 93% 1

Intra-abdominal Infections

  • First-line: Linezolid 600 mg IV/PO q12h (Strong recommendation, 1C) 1
  • Alternative: Tigecycline 100 mg IV loading dose, then 50 mg IV q12h (Weak recommendation, 2D) 1
    • Tigecycline achieves high peritoneal penetration, making it ideal for IAI 1
    • Do NOT use tigecycline for bacteremia due to low serum levels from large volume of distribution 1
  • Duration: 5-7 days based on clinical response 1

Uncomplicated Urinary Tract Infections

Multiple oral options available (all Weak recommendations, 2D):

  • Fosfomycin: 3 g PO single dose 1
  • Nitrofurantoin: 100 mg PO q6h 1
  • High-dose ampicillin: 18-30 g IV daily in divided doses 1
  • Amoxicillin: 500 mg PO/IV q8h 1
  • Duration: 3-7 days 1

Critical caveat: 82% of VRE E. faecalis isolates remain ampicillin-susceptible despite vancomycin resistance 2. High urinary ampicillin concentrations can overcome resistance in UTIs, achieving clinical/microbiological eradication rates of 88.1%/86% even in ampicillin-resistant VRE 1

Complicated Urinary Tract Infections

  • First-line: Linezolid 600 mg IV/PO q12h (Strong recommendation, 1C) 1
  • Alternative: Daptomycin 6-12 mg/kg IV daily (Weak recommendation, 2D) 1
  • Duration: 5-7 days 1

Pneumonia

  • Linezolid 600 mg IV q12h (Strong recommendation, 1C) 1
  • Duration: At least 7 days 1

Critical Clinical Pearls

Avoid common pitfalls:

  • Never use tigecycline for bacteremia—low serum levels make it ineffective despite in vitro activity 1
  • Daptomycin requires dose escalation for bacteremia: Standard 6 mg/kg is insufficient; use 8-12 mg/kg 1
  • β-lactam combinations with daptomycin work best at high daptomycin doses (≥9 mg/kg) and lower MICs (≤2 mg/L) 1
  • Don't overlook ampicillin for UTIs: Despite being VRE, most E. faecalis remains ampicillin-susceptible 2

Stewardship concern: Daptomycin is frequently overused (19% of cases) despite 82% ampicillin susceptibility in VRE E. faecalis 2. Always check susceptibilities before defaulting to broad-spectrum agents.

Combination therapy considerations:

  • Reserve for severely ill patients, treatment failures, or high daptomycin MIC (3-4 mg/mL) 1
  • Daptomycin + β-lactams shows synergy, particularly with ampicillin or ceftaroline 1
  • Limited data exists for other combinations (gentamicin, rifampin, linezolid combinations) 1

Endocarditis: Requires cardiac surgery consultation combined with antimicrobial therapy 1

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.